Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering p H.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Treatment of hypochloremic metabolic alkalosis,Acidification of urine (e.g., to enhance renal clearance of basic drugs like amphetamine or quinidine),Adjunct in the treatment of severe refractory metabolic alkalosis
Osteoarthritis,Rheumatoid arthritis
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 m L/kg/hour, typically 500-1000 m L over 4-8 hours, adjusted based on serum chloride and p H. Maximum infusion rate: 1 m L/kg/hour.
600 mg orally once daily; max 1200 mg/day
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Hepatic: ammonium chloride is converted to urea (via the urea cycle) and hydrochloric acid; enzymes include carbamoyl phosphate synthetase I, ornithine transcarbamylase, and arginase.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
<10% bound to plasma proteins.
>99% bound primarily to albumin.
0.3-0.5 L/kg; distributes primarily in extracellular fluid.
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: ~100% (well absorbed); IV: 100% (bioequivalent).
Oral: approximately 80-90%.
GFR <30 m L/min: Avoid use due to risk of hyperchloremic metabolic acidosis and ammonium accumulation. GFR 30-50 m L/min: Initiate at 50% of standard rate, monitor serum ammonium and electrolytes. No adjustment for GFR >50 m L/min.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh Class B or C: Contraindicated due to impaired urea synthesis and risk of hepatic encephalopathy. Child-Pugh Class A: Caution; monitor serum ammonia and reduce infusion rate by 50%.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
Children: Initial dose 0.5-1 m Eq/kg of ammonium ion (1 m Eq/kg = 0.1 m L/kg of 0.9% solution) as a slow IV infusion over 4-6 hours. Maximum rate: 0.5 m L/kg/hour. Titrate based on serum p H and chloride.
Not approved for pediatric use
Use with caution due to age-related decline in renal function; start at lower end of dosing range (0.5 m L/kg/hour) and monitor renal function and electrolytes closely. Adjust dose per renal function.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
None
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Use with caution in patients with hepatic impairment (risk of hyperammonemia and hepatic encephalopathy), renal impairment (risk of metabolic acidosis), or respiratory acidosis. Monitor serum ammonia, chloride, bicarbonate, and p H levels. Rapid infusion may cause local irritation, phlebitis, and metabolic acidosis.
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Severe hepatic insufficiency (cirrhosis, hepatitis), severe renal impairment (anuria, oliguria), primary respiratory acidosis, hypernatremia, and known hypersensitivity to any component.
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Avoid high-sodium foods or salt substitutes that contain potassium, as this may affect electrolyte balance. No specific food restrictions are required, but maintain a balanced diet as advised by your healthcare provider.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
Ammonium chloride is a urine acidifier with limited data in pregnancy. It is generally considered low risk for teratogenicity based on animal studies and lack of human adverse reports. However, maternal metabolic acidosis from overdose could theoretically harm the fetus. First trimester: no known teratogenic effect. Second and third trimesters: minimal risk unless maternal acidosis occurs. Use only if clearly needed.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Ammonium chloride is excreted into breast milk, but concentrations are low and not expected to harm the nursing infant. The M/P ratio is unknown. It is considered compatible with breastfeeding if used at recommended doses. Monitor infant for signs of acidosis if high doses are used.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
Pregnancy does not typically require dose adjustment. However, consider the increased renal clearance and plasma volume in pregnancy; monitor acid-base balance closely. No established dosing change is recommended; use the lowest effective dose.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
0.9% ammonium chloride in normal saline is an acidifying agent used to correct metabolic alkalosis. Monitor serum electrolytes, p H, and bicarbonate closely during infusion. Avoid in patients with severe hepatic or renal impairment. Administer via central line due to hypertonicity (approximately 900 m Osm/L). Can cause hyperammonemia in hepatic failure; use with caution in hypokalemia as it may exacerbate potassium loss.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
This medication is given intravenously to treat alkalosis (high blood p H).,You may experience pain or burning at the IV site; report any discomfort.,Tell your doctor if you have liver or kidney disease.,Do not take potassium supplements or salt substitutes without consulting your doctor.,Inform your healthcare provider of all medications you are taking.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs DAYPRO, answered by our medical review team.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is a Expectorant/Systemic Acidifier that works by Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering p H.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is: Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 m L/kg/hour, typically 500-1000 m L over 4-8 hours, adjusted based on serum chloride and p H. Maximum infusion rate: 1 m L/kg/hour.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is classified as Category C. Ammonium chloride is a urine acidifier with limited data in pregnancy. It is generally considered low risk for teratogenicity based on animal studies and lack of human adverse repo. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.